Physician profile
John G Horner
NPI 1598997298
$1,815.97
in general payments reported to CMS, 2019-2025
23 companies · $98.34 in 2025
The $98.34 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $348 · 2020: $457 · 2021: $286 · 2022: $345 · 2023: $161 · 2024: $120 · 2025: $98.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $378.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $363.11 | 2019-2025 | Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $317.45 | 2019-2023 | Xifaxan |
| Lilly USA, LLC | $179.77 | 2019-2024 | Zepbound, Mounjaro |
| Horizon Therapeutics Plc | $125.00 | 2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.02 | 2019-2022 | |
| Glaxosmithkline, LLC. | $99.64 | 2019-2023 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $95.39 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $80.26 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $56.02 | 2019-2022 | |
| Pfizer INC. | $53.81 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $47.15 | 2020-2021 | |
| Abbvie INC. | $45.55 | 2020-2025 | |
| Corcept Therapeutics | $40.22 | 2020-2022 | |
| Avanir Pharmaceuticals, INC. | $36.41 | 2019 | |
| Allergan, INC. | $36.35 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $26.80 | 2021 | |
| Lundbeck LLC | $24.66 | 2025 | Vyepti |
| Amarin Pharma, INC. | $16.10 | 2019 | |
| Amgen INC. | $14.68 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.54 | 2020 | |
| Axsome Therapeutics, INC. | $14.15 | 2025 | Auvelity |
| Biogen, INC. | $12.08 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $11.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Horner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.